View Post

Adding Alpelisib to Fulvestrant Doesn’t Impact HRQOL in Advanced Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Sucharita Mistry, PhD From: cancertherapyadvisor.com Data on health-related quality of life (HRQOL) suggest alpelisib plus fulvestrant is a well-tolerated treatment option for patients with PIK3CA-mutated, advanced breast cancer, according to researchers. They reported their findings in the Journal of Clinical Oncology.1 The researchers found no “clinically meaningful differences” in HRQOL between patients who received alpelisib plus fulvestrant and those …

View Post

RIBECCA Trial Confirms Role of Ribociclib Combination in HR+ HER2-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Danielle Ternyila From: targetedonc.com In recent years, the role of ribociclib in hormone receptor (HR)-positive HER2-negative advanced breast cancer has been investigated in phase III clinical trial, as monotherapy or in combination with other drugs like letrozole (Femara, NCT01958021) and fulvestrant (NCT02422615). RIBECCA is an open-label multicenter phase IIIb clinical trial which was conducted in Germany to further validate …